Tpna - tpna.com - Takeda U.S. Press Release
General Information:
Latest News:
Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimer’... 26 Aug 2013 | 10:00 am
Osaka, Japan, August 27, 2013 and Durham, NC, August, 26, 2013 – Takeda Pharmaceutical Company Limited (“Takeda”) and its partner, Zinfandel Pharmaceuticals, Inc. (“Zinfandel”), today announced the in...
Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcer... 21 Aug 2013 | 10:00 am
Osaka, Japan – August 21, 2013 – Takeda Pharmaceutical Company Limited (“Takeda”) today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal ...
Takeda and Zinfandel Pharmaceuticals Announce Results of a Study of the Performance Characteristics of a Genetics-Based Biomarker Risk Assignment Algo... 17 Jul 2013 | 10:00 am
Osaka, Japan, July 18, 2013, Deerfield, Ill. and Durham, NC, July, 17, 2013 – Takeda Pharmaceutical Company Limited (“Takeda”) and its wholly-owned subsidiary, Takeda Development Center Americas, Inc....
Pro Athletes Team Up to Champion Gout Awareness, Emmitt Smith Joins Professional Basketball, Baseball and Racing Stars in Partnering with Takeda on Go... 9 Jul 2013 | 10:00 am
Deerfield, Ill., July 9, 2013 – For Emmitt Smith, Pro Football running back legend, as an athlete, pain was a part of the job. Yet he describes a gout flare as a level of pain like nothing else he had...
Takeda Ranked Among Chicago’s Best and Brightest Companies , Company’s continued excellence in employee engagement recognized for second consecutive y... 2 Jul 2013 | 10:00 am
Deerfield, Ill., July 2, 2013 – The National Association for Business Resources (NABR) has listed Takeda among Chicago’s 101 Best and Brightest Companies to Work For™. Named for the second consecutive...
Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohn’s Disease and Ulcerati... 21 Jun 2013 | 10:00 am
Deerfield, Ill. and Osaka, Japan, June 21, 2013 – Takeda Pharmaceutical Company Limited (“Takeda”) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a Biologic...
Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and piog... 17 Jun 2013 | 10:00 am
Deerfield, Ill., June 17, and Osaka, Japan, June 18, 2013 – Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that NES...
Takeda and Lundbeck Present Results from Pivotal Phase 3 Clinical Trials with Vortioxetine, an Investigational Compound for Major Depressive Disorder,... 18 May 2013 | 10:00 am
San Francisco, California – May 18, 2013 – Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the companies will be presenting new data from four studie...
Takeda to Acquire Inviragen, Inc., Obtains Promising Vaccine Candidates Against Dengue and Hand, Foot and Mouth Disease, Advancing Takeda’s Commitment... 7 May 2013 | 10:00 am
Osaka, Japan, May 8, 2013, Deerfield, IL and Fort Collins, CO, U.S.A., May 7, 2013 – Takeda Pharmaceutical Company Limited (“Takeda”) and Inviragen, Inc. (“Inviragen”) jointly announced today that Tak...
Judge Nullifies Verdict in Diabetes Drug Case 1 May 2013 | 10:00 am
Deerfield, Ill., May 1, 2013 – Takeda Pharmaceuticals U.S.A., Inc. announced today that in the case of Jack Cooper, et al. v. Takeda Pharmaceuticals America, Inc., et al., No. CGC-12-518535, the judge...
